Related Experiment Videos
[Acellular pertussis vaccine (Pa)]
1Zakład Epidemiologii Państwowego Zakładu Higieny w Warszawie.
Insights
Whole-cell pertussis vaccines (Pw) reduced pertussis deaths, but acellular pertussis vaccines (Pa) offer a safer, less reactive alternative. Acellular vaccines are effective for booster doses in children and adults, potentially curbing pertussis spread.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Context:
- Whole-cell pertussis vaccine (Pw) historically reduced pertussis morbidity and mortality.
- High reactogenicity of Pw prompted research into less reactogenic alternatives.
- Acellular pertussis vaccine (Pa) emerged as an effective, safer, and less reactogenic option.
Purpose:
- To evaluate the efficacy and safety of acellular pertussis vaccines (Pa) compared to whole-cell pertussis vaccines (Pw).
- To explore the role of acellular pertussis vaccines (Pa) in booster doses for older children and adults.
- To address the increasing pertussis morbidity observed in certain regions.
Summary:
- Acellular pertussis vaccine (Pa) is effective, safe, and less reactogenic than whole-cell pertussis vaccine (Pw).
- Pa is suitable for booster doses in older children and adults, who may be sources of pertussis infection for infants.
- Current trends show increasing pertussis incidence in some areas, necessitating updated vaccination strategies.
Impact:
- Acellular pertussis vaccines (Pa) can be used for primary vaccination in some countries.
- Pa introduction as booster doses for 6-7-year-olds may be considered if pertussis epidemiology in school-aged children remains unsatisfactory.
- Improved pertussis control through safer and effective vaccination strategies.
Abstract:
Vaccination by whole-cell pertussis vaccine (Pw) since forties years was followed by decreasing of morbidity and especially mortality caused by pertussis. High reactogenicity of this vaccine (Pw) was the reason trials undertaken to search new type of less reactogenic vaccine. Acellular pertussis vaccine (Pa) was found as effective, safe, small reactogenic. It may be especially used as booster doses for older children and even for adults people. Actual pertussis infection among adults are suspected as the source infection for children. Just now in some countries acellular vaccine start to be used for ground vaccination of children. Increasing of morbidity of pertussis was noted in some provinces in Poland in last time. Acellular pertussis vaccine may be introduced as booster dose for 6-7 years old children, if epidemiological situation of pertussis among school-age children would be not satisfied in future.